Clinical trials: Hepatobiliary Disorders
NAFLD, Diabetes
GLP-1 RA on Liver OMICS in MASLD
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue.
- Conditions
- NAFLD, Diabetes, Obesity
- Trial name
- OMICS in MASLD (NCT06982378)
- Testing
- GLP-1 receptor agonist
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT07294963
- Testing
- Structured Mediterranean Diet, Control / General Advice
- Where
- 2 sites in Pakistan
- Volunteers
- 45 people
- Sponsor
- Khyber Medical University Peshawar
Non-alcoholic Fatty Liver Disease (NAFLD)
Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence.
A key element in the diagnosis of non-alcoholic fatty liver disease (NAFLD) is the differentiation of non-alcoholic steatohepatitis (NASH) from non-alcoholic fatty liver (NAFL) and the staging of the liver fibrosis, given that…
- Trial name
- NASHAI (NCT04099147)
- Testing
- This is an observational study.
- Volunteers
- 14,046 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Hepatic Fat Accumulation, Nonalcoholic Fatty Liver Disease
Dietary Protein and Hepatic Fat Accumulation
The objective of this study is to investigate the potential beneficial effect of increasing protein in the diet in order to decrease hepatic lipid accumulation on a high-fat diet.
- Trial name
- LiF-Pro (NCT01354626)
- Testing
- dietary protein, low-protein
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Wageningen University
Single-ventricle, Hepatic Congestion
The Effect of Fontan Fenestration Closure on Hepatic Stiffness
The overarching goal of this project is to discern how closure of Fontan fenestrations in patients with single ventricle heart disease will affect hepatic congestion, a major determinant of chronic liver disease.
- Trial name
- NCT03481985
- Testing
- Fenestration status
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Boston Children's Hospital
Nonalcoholic Fatty Liver Disease
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is one of the most common chronic liver diseases worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of the disease which runs a progressive course and may result in liver cirrhosis…
- Trial name
- NCT01210989
- Testing
- Phyllanthus urinaria
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Non Alcoholic Steatohepatitis
Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis
120 patients of biopsy proven NASH will be randomized into two groups. Cases group will receive combination of pentoxiphylline and Vitamin E, and control group will receive only Vitamin E.
- Trial name
- NCT01384578
- Testing
- pentoxiphylline and Vitamin E, Vitamin E
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Disease Chronic, Muscle Weakness
Inspiratory Muscle Training Post-Liver Transplant
Individuals with chronic liver disease develop significant muscle wasting that remains post-liver transplant. The transplant surgery additionally challenges respiratory mechanics.
- Conditions
- Liver Disease Chronic, Muscle Weakness, Respiratory Insufficiency
- Trial name
- NCT03130608
- Testing
- Inspiratory Muscle Training
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Miami
Nonalcoholic Fatty Liver Disease
Observational Study About Patients Diagnosed With NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome.
- Trial name
- NCT05625750
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Non-Alcoholic Steatohepatitis (NASH)
Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this study is to assess the safety, the tolerability and the short term effect on liver enzymes of TRO19622 500 mg for one month in patients with Non-Alcoholic Steatohepatitis (NASH).
- Trial name
- NCT00666016
- Testing
- TRO19622
- Where
- 5 sites in France
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Moderate Liver Impairment, Severe Liver Impairment
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment.
- Trial name
- NCT04634149
- Testing
- BMS-986036
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Liver Disease
Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated…
- Trial name
- NCT07682363
- Testing
- No treatment is given
- Where
- China
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Liver Disease Chronic, Hepatitis B Virus
Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.
Background: Cirrhotic patients have an increased risk of infections. In these patients is important to prevent hepatitis B virus (HBV) infection, as it may cause a deterioration of liver function.
- Trial name
- NCT03459521
- Testing
- Fendrix or HBVAXPRO 40
- Where
- Spain
- Volunteers
- 125 people
- Sponsor
- Corporacion Parc Tauli
Non-alcoholic Fatty Liver Disease, Cholesterol Ester Storage Disease
Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study
Non-alcoholic fatty liver disease (NAFLD) is a world-wide problem with a global prevalence estimated at 1.5 billion people. It is characterised by significant diversity and phenotypic heterogeneity.
- Trial name
- NCT01791452
- Where
- Israel
- Sponsor
- Assy Nimer
Alcoholic Liver Disease
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients.
- Trial name
- NCT03503708
- Testing
- Livitol-70
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Composite Interceptive Med Science
Non-alcoholic Fatty Liver Disease
A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - Food Effect (FE) phase, and Part C - multiple ascending dose (MAD) phase.
- Trial name
- NCT05063968
- Testing
- XZP-6019 tablet
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
This study involves research about an investigational medicine called Amlexanox. The reason for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver…
- Conditions
- Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01975935
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan
Obesity, Non-Alcoholic Steatohepatitis
EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity
This study is designed to investigate the impact of weight loss achieved with the IGB on NASH with early fibrosis in a select cohort of patients with obesity preselected to have a high pre-test probability of having NASH with…
- Trial name
- NCT02880189
- Testing
- Orbera Intragastric Balloon, Endoscopic Ultrasound Guided Core Liver Biopsy
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Colorectal Cancer, Liver Metastases
Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
To evaluate whether a combination regimen of pentoxifylline, ursodeoxycholic acid and enoxaparin provides a protective effect on the liver parenchyma after high dose rate (HDR) brachytherapy.
- Conditions
- Colorectal Cancer, Liver Metastases, Irradiation Damage, Radiation Induced Liver Disease
- Trial name
- ELDORADO (NCT01149304)
- Testing
- Pentoxifylline, Ursodeoxycholic Acid, Enoxaparin
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- University of Magdeburg
Alagille Syndrome
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
The purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (LUM001 also known as Maralixibat) in children with ALGS who have completed participation in a core LUM001…
- Trial name
- IMAGINE (NCT02047318)
- Testing
- LUM001 (Maralixibat)
- Where
- 3 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.